CORRESP Filing
Akari Therapeutics Plc
Date: Jan. 27, 2026 · CIK: 0001541157 · Accession: 0001493152-26-003763
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292930
Letter
Akari Therapeutics, Plc
East Jackson St, Suite 3300
Tampa, FL 33602
January 27, 2026
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, D.C. 20549-7553
Re: Akari Therapeutics, Plc
Registration Statement on Form S-1
Filed January 23, 2026 (File No. 333-292930)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the " Company ") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-292930) (the " Registration Statement ") be accelerated so that the Company's Registration Statement will become effective at 4:15 P.M., Eastern Time, on January 29, 2026, or as soon thereafter as is practicable.
Please contact Gary Emmanuel, Esq. of Greenberg Traurig, P.A, counsel to the Company, at 212 801 9337 to provide notice of effectiveness, or if you have any questions or comments concerning this request.
Very
truly yours,
AKARI
THERAPEUTICS, PLC
Show Raw Text
CORRESP 1 filename1.htm Akari Therapeutics, Plc 401 East Jackson St, Suite 3300 Tampa, FL 33602 January 27, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Akari Therapeutics, Plc Registration Statement on Form S-1 Filed January 23, 2026 (File No. 333-292930) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the " Company ") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-292930) (the " Registration Statement ") be accelerated so that the Company's Registration Statement will become effective at 4:15 P.M., Eastern Time, on January 29, 2026, or as soon thereafter as is practicable. Please contact Gary Emmanuel, Esq. of Greenberg Traurig, P.A, counsel to the Company, at 212 801 9337 to provide notice of effectiveness, or if you have any questions or comments concerning this request. Very truly yours, AKARI THERAPEUTICS, PLC By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: President and Chief Executive Officer